Tilray Brands, Inc. (TLRY)
NASDAQ: TLRY · Real-Time Price · USD
6.66
+0.21 (3.26%)
At close: Mar 24, 2026, 4:00 PM EDT
6.76
+0.10 (1.50%)
Pre-market: Mar 25, 2026, 4:39 AM EDT
Tilray Brands Revenue
Tilray Brands had revenue of $217.51M in the quarter ending November 30, 2025, with 3.11% growth. This brings the company's revenue in the last twelve months to $837.32M, up 0.98% year-over-year. In the fiscal year ending May 31, 2025, Tilray Brands had annual revenue of $821.31M with 4.10% growth.
Revenue (ttm)
$837.32M
Revenue Growth
+0.98%
P/S Ratio
0.93
Revenue / Employee
$294,625
Employees
2,842
Market Cap
775.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 821.31M | 32.37M | 4.10% |
| May 31, 2024 | 788.94M | 161.82M | 25.80% |
| May 31, 2023 | 627.12M | -1.25M | -0.20% |
| May 31, 2022 | 628.37M | 115.29M | 22.47% |
| May 31, 2021 | 513.09M | 302.60M | 143.77% |
| Dec 31, 2020 | 210.48M | -194.84M | -48.07% |
| May 31, 2020 | 405.33M | 27.87M | 7.38% |
| Dec 31, 2019 | 377.46M | 198.16M | 110.52% |
| Jun 30, 2019 | 179.30M | 136.17M | 315.73% |
| Dec 31, 2018 | 43.13M | - | - |
| Jun 30, 2018 | 43.13M | 22.59M | 110.00% |
| Dec 31, 2017 | 20.54M | - | - |
| Jun 30, 2017 | 20.54M | 7.89M | 62.43% |
| Dec 31, 2016 | 12.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 887.40M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 588.90M |
| Esperion Therapeutics | 403.14M |
| Ironwood Pharmaceuticals | 296.15M |
| Kamada | 180.46M |
| Cronos Group | 146.59M |
TLRY News
- 9 hours ago - Craft beer BrewDog to launch in Hamptons after Tilray CEO buys troubled brewer - New York Post
- 5 days ago - Tilray stock price has just lost a key support: is a crash to $5 coming? - Invezz
- 5 days ago - Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia - GlobeNewsWire
- 6 days ago - Breckenridge Distillery Expands Its Colorado Presence with Cheba Hut Partnership - GlobeNewsWire
- 12 days ago - Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance with “gesund leben” Cooperation and Alliance Healthcare Deutschland to Accelerate Market Expansion and Strengthen Pharmacy Access Across Germany - GlobeNewsWire
- 13 days ago - Lighter. Cheaper. Funner. Pub Light Is Here. - GlobeNewsWire
- 14 days ago - Canadian Cannabis Stocks to Watch in March 2026 as Global Legalization Expands - MarijuanaStocks
- 15 days ago - Tilray's Going To Be Great, But For Now It's A Hold - Seeking Alpha